Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or

 Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...

Related Keywords

Copenhagen ,Køavn ,Denmark ,United States ,Japan ,Spain ,Netherlands ,Tokyo ,New Jersey ,Iceland ,Barcelona ,Comunidad Autonoma De Cataluna ,Liechtenstein ,Norway ,Genmab Duobody ,Institut Catal ,Marisol Peron ,Anna Sureda ,Andrew Carlsen ,Global Communications Corporate Affairs ,Twitter ,Abbvie Biotechnology Ltd ,Development Of Novel Anti ,Exchange Commission ,European Medicines Agency ,European Union ,Administration Of Tepkinly ,Macrophage Propertiesj Immunol ,Company Announcement ,European Commission ,Chief Executive Officer ,Full Prescribing Information ,Medication Guide ,Important Safety Information ,Lysis Syndrome ,Product Characteristics ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Largeb Cell Lymphoma ,European Medicines ,Conditional Marketing ,Accessed August ,Accessed July ,Published Online September ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci ,Senior Vice President ,Global Communications ,Corporate Affairs ,Vice President ,Investor Relations ,